BRAF and colorectal carcinoma: In this study, we identified the antiepileptic VPA, a widely used HDACi, as the best agent to potentiate dual-OXA/fluoropyrimidine chemotherapy efficacy and overcome chemotherapy resistance in wild-type and BRAF- and RAS-mutated CSC-enriched primary spheroid CRC cultures via low-throughput epigenetic drug screening.